Rong Hai, Ph.D.
Affiliations: | 2006 | University of California, Berkeley, Berkeley, CA, United States |
Area:
Virology BiologyGoogle:
"Rong Hai"Parents
Sign in to add mentor| Fenyong Liu | grad student | 2006 | UC Berkeley | |
| (Functional investigation of US15 in human cytomegalovirus (HCMV) infection in retinal pigment epithelial (RPE) cells.) | ||||
| Peter Palese | post-doc | 2007-2015 | MSSM | |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Dulin H, Barre RS, Xu D, et al. (2024) Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2. Journal of Virology. e0157123 |
| Biswal M, Yao W, Lu J, et al. (2024) A conformational selection mechanism of flavivirus NS5 for species-specific STAT2 inhibition. Communications Biology. 7: 76 |
| Chavez JR, Yao W, Dulin H, et al. (2023) Modeling the effects of cigarette smoke extract on influenza B virus infections in mice. Frontiers in Immunology. 14: 1083251 |
| Dulin H, Hendricks N, Xu D, et al. (2022) Impact of Protein Nitration on Influenza Virus Infectivity and Immunogenicity. Microbiology Spectrum. e0190222 |
| Wang A, Hai R, Rider PJ, et al. (2022) Noncoding RNAs and Deep Learning Neural Network Discriminate Multi-Cancer Types. Cancers. 14 |
| Chavez J, Hai R. (2021) Effects of Cigarette Smoking on Influenza Virus/Host Interplay. Pathogens (Basel, Switzerland). 10 |
| Carreño JM, Strohmeier S, Kirkpatrick Roubidoux E, et al. (2020) H1 Hemagglutinin Priming Provides Long-Lasting Heterosubtypic Immunity against H5N1 Challenge in the Mouse Model. Mbio. 11 |
| Wang B, Thurmond S, Zhou K, et al. (2020) Structural basis for STAT2 suppression by flavivirus NS5. Nature Structural & Molecular Biology |
| Bernstein DI, Guptill J, Naficy A, et al. (2019) Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. The Lancet. Infectious Diseases |
| Bailey MJ, Duehr J, Dulin H, et al. (2018) Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model. Nature Communications. 9: 4560 |